Cencora (COR) Income Statement Analysis

See more : Jaws Spitfire Acquisition Corporation (SPFR) Income Statement Analysis – Financial Results

Complete financial analysis of Cencora (COR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cencora, a leading company in the Medical – Distribution industry within the Healthcare sector.

You may be interested

Cencora (COR)

Industry: Medical - Distribution

Sector: Healthcare

Website: https://www.amerisourcebergen.com

About Cencora

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994
Revenue	293.96B	262.17B	238.59B	213.99B	189.89B	179.59B	167.94B	153.14B	146.85B	135.96B	119.57B	87.96B	78.08B	80.22B	77.95B	71.76B	70.19B	66.07B	61.20B	54.58B	53.18B	49.66B	45.23B	16.19B	11.65B	9.81B	8.67B	7.82B	5.55B	4.67B	4.30B
Cost of Revenue	284.05B	253.21B	230.25B	207.21B	184.70B	174.45B	163.36B	148.60B	142.71B	132.50B	116.61B	85.47B	75.46B	77.68B	75.60B	69.66B	68.14B	63.75B	58.97B	52.60B	51.00B	47.41B	43.21B	15.49B	11.12B	9.33B	8.25B	7.43B	5.25B	4.40B	4.06B
Gross Profit	9.91B	8.96B	8.33B	6.77B	5.20B	5.14B	4.58B	4.54B	4.14B	3.46B	2.96B	2.48B	2.62B	2.54B	2.36B	2.10B	2.05B	2.33B	2.23B	1.98B	2.18B	2.25B	2.02B	700.12M	520.89M	475.60M	423.10M	389.30M	304.90M	268.80M	243.30M
Gross Profit Ratio	3.37%	3.42%	3.49%	3.17%	2.74%	2.86%	2.73%	2.97%	2.82%	2.55%	2.47%	2.83%	3.36%	3.17%	3.02%	2.93%	2.92%	3.52%	3.65%	3.63%	4.10%	4.53%	4.48%	4.32%	4.47%	4.85%	4.88%	4.98%	5.49%	5.76%	5.66%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	80.57M	76.39M	67.79M	61.67M	58.00M	55.25M	48.24M	46.98M	44.62M	41.06M	20.83M	6.46M	5.47M	1.41B	1.40B	1.26B	1.21B	1.29B	1.22B	408.76M	303.04M	281.80M	254.90M	255.40M	195.40M	160.90M	150.70M
Selling & Marketing	0.00	0.00	0.00	0.00	23.73M	2.66B	21.02M	18.18M	17.50M	15.93M	14.55M	14.41M	10.33M	5.74M	1.47M	135.00K	170.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	5.66B	5.31B	4.85B	3.59B	2.77B	2.66B	88.81M	79.85M	75.50M	71.18M	62.79M	61.38M	54.95M	1.20B	1.16B	1.13B	1.12B	1.41B	1.40B	1.26B	1.21B	1.29B	1.22B	408.76M	303.04M	281.80M	254.90M	255.40M	195.40M	160.90M	150.70M
Other Expenses	2.07B	49.04M	27.35M	41.74M	1.58M	12.95M	141.71M	129.43M	108.78M	95.75M	80.78M	66.06M	64.94M	78.09M	33.90M	12.98M	10.09M	91.22M	86.01M	86.46M	75.77M	70.99M	61.15M	18.87M	17.42M	19.90M	16.60M	14.30M	11.60M	10.10M	14.70M
Operating Expenses	7.73B	6.27B	5.54B	4.10B	3.16B	3.13B	230.52M	209.28M	184.27M	166.94M	143.58M	127.45M	119.89M	1.33B	1.25B	1.20B	1.21B	1.50B	1.48B	1.34B	1.29B	1.36B	1.28B	427.63M	320.46M	301.70M	271.50M	269.70M	207.00M	171.00M	165.40M
Cost & Expenses	291.78B	259.49B	235.83B	211.15B	187.86B	177.58B	402.11M	357.01M	305.74M	268.89M	226.27M	200.16M	189.89M	79.01B	76.85B	70.86B	69.35B	65.25B	60.45B	53.94B	52.29B	48.77B	44.49B	15.92B	11.44B	9.63B	8.52B	7.70B	5.45B	4.57B	4.22B
Interest Income	0.00	228.93M	21.31M	8.47M	20.64M	37.71M	14.94M	3.86M	35.00K	6.00K	6.00K	32.00K	13.00K	2.18M	2.31M	3.00K	17.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	156.99M	228.93M	210.67M	182.54M	137.88M	157.77M	33.16M	22.47M	11.28M	5.86M	3.41M	950.00K	5.24M	78.90M	72.49M	58.31M	2.50M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.09B	972.39M	697.94M	505.17M	401.62M	488.54M	499.64M	422.92M	385.03M	95.70M	80.72M	65.79M	64.33M	108.31M	86.46M	78.91M	95.88M	104.34M	96.93M	90.88M	87.09M	80.44M	66.58M	24.71M	17.42M	19.90M	16.60M	14.30M	11.60M	10.10M	14.70M
EBITDA	3.25B	3.41B	3.11B	2.91B	-4.75B	1.65B	1.87B	1.49B	1.92B	633.99M	950.96M	1.07B	1.45B	1.33B	1.20B	977.61M	921.72M	926.76M	845.64M	727.83M	988.05M	966.57M	809.25M	297.20M	217.85M	193.80M	185.00M	133.90M	109.50M	107.90M	92.60M
EBITDA Ratio	1.11%	1.41%	1.46%	1.59%	1.28%	1.39%	0.15%	0.15%	0.12%	0.10%	0.09%	0.10%	0.10%	1.64%	1.53%	1.36%	1.35%	1.41%	1.37%	1.55%	1.87%	1.95%	1.84%	1.90%	1.86%	2.13%	2.25%	1.71%	1.97%	2.31%	6.33%
Operating Income	2.18B	2.34B	2.37B	2.35B	-5.14B	1.11B	142.28M	124.81M	94.62M	64.41M	46.15M	34.67M	17.04M	1.20B	1.10B	883.75M	827.86M	820.34M	748.71M	636.95M	890.43M	883.11M	718.43M	259.38M	200.43M	173.90M	151.60M	119.60M	97.90M	97.80M	77.90M
Operating Income Ratio	0.74%	0.89%	0.99%	1.10%	-2.70%	0.62%	0.08%	0.08%	0.06%	0.05%	0.04%	0.04%	0.02%	1.50%	1.42%	1.23%	1.18%	1.24%	1.22%	1.17%	1.67%	1.78%	1.59%	1.60%	1.72%	1.77%	1.75%	1.53%	1.76%	2.09%	1.81%
Total Other Income/Expenses	-171.27M	-285.68M	-183.32M	-132.34M	-158.48M	-899.42M	-266.26M	-142.46M	-134.86M	-153.26M	-112.23M	-73.94M	-66.88M	-72.10M	-87.47M	-59.68M	-66.52M	-35.29M	-8.08M	-168.12M	-140.59M	-156.98M	-146.38M	-56.54M	-40.73M	-54.60M	-84.80M	-54.70M	-35.80M	-52.30M	-242.50M
Income Before Tax	2.00B	2.16B	2.18B	2.22B	-5.29B	967.11M	106.75M	100.67M	82.04M	57.02M	40.09M	32.01M	11.82M	1.13B	1.03B	824.07M	761.34M	785.05M	740.63M	468.83M	760.37M	726.13M	572.05M	202.83M	159.70M	119.30M	82.80M	78.00M	62.00M	45.50M	-164.60M
Income Before Tax Ratio	0.68%	0.82%	0.91%	1.04%	-2.79%	0.54%	0.06%	0.07%	0.06%	0.04%	0.03%	0.04%	0.02%	1.41%	1.32%	1.15%	1.08%	1.19%	1.21%	0.86%	1.43%	1.46%	1.26%	1.25%	1.37%	1.22%	0.96%	1.00%	1.12%	0.97%	-3.83%
Income Tax Expense	484.70M	428.26M	516.52M	677.25M	-1.89B	112.97M	-10.00K	174.00K	119.00K	163.00K	38.00K	401.00K	1.10M	424.02M	391.02M	312.22M	292.27M	291.28M	272.62M	176.90M	291.98M	284.90M	227.11M	77.73M	60.69M	48.40M	32.30M	30.60M	19.30M	17.30M	7.80M
Net Income	1.51B	1.75B	1.70B	1.54B	-3.41B	855.37M	77.92M	74.86M	58.71M	34.71M	22.77M	18.84M	5.05M	706.62M	636.75M	503.40M	250.56M	469.17M	467.71M	319.20M	468.39M	441.23M	344.94M	125.10M	99.01M	67.50M	50.50M	45.40M	35.50M	10.20M	-207.70M
Net Income Ratio	0.51%	0.67%	0.71%	0.72%	-1.80%	0.48%	0.05%	0.05%	0.04%	0.03%	0.02%	0.02%	0.01%	0.88%	0.82%	0.70%	0.36%	0.71%	0.76%	0.58%	0.88%	0.89%	0.76%	0.77%	0.85%	0.69%	0.58%	0.58%	0.64%	0.22%	-4.83%
EPS	7.60	8.62	8.15	7.48	-16.65	4.07	0.35	0.34	0.26	0.16	0.10	0.08	0.02	2.59	2.26	1.67	0.78	1.26	1.14	0.63	1.07	0.99	0.82	0.54	0.48	0.33	0.21	0.24	0.20	0.07	-5.19
EPS Diluted	7.53	8.53	8.04	7.39	-16.65	4.04	2.22	2.20	1.79	1.35	1.05	0.88	0.24	2.54	2.22	1.66	0.77	1.25	1.13	0.62	1.01	0.98	0.79	0.53	0.48	0.33	0.21	0.24	0.19	0.07	-5.19
Weighted Avg Shares Out	198.50M	202.51M	208.47M	205.92M	204.78M	210.17M	220.24M	222.25M	225.94M	217.79M	234.81M	234.97M	257.22M	272.47M	282.26M	300.57M	321.28M	370.36M	410.02M	425.26M	447.35M	435.38M	419.74M	228.74M	206.21M	202.79M	190.71M	198.35M	182.05M	145.71M	40.00M
Weighted Avg Shares Out (Dil)	200.28M	204.59M	211.21M	208.47M	204.78M	211.84M	35.14M	34.06M	32.73M	25.71M	21.74M	21.50M	20.99M	277.72M	287.25M	302.75M	324.92M	375.77M	414.89M	431.08M	471.12M	463.82M	448.91M	251.23M	208.08M	206.73M	202.85M	200.42M	184.42M	145.71M	40.00M

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

November 6, 2024businesswire.com

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the...

Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America

November 6, 2024businesswire.com

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management services organization (MSO) of retina specialists, from Webster Equity Partners. “The acquisition of RCA...

Cencora to Report Q4 Earnings: What's in Store for the Stock?

November 4, 2024zacks.com

COR's fiscal fourth-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

Dividend Aristocrats Of The Future - Part 3

November 1, 2024seekingalpha.com

This is the final group of 10 companies scheduled to reach dividend aristocrat status, sometime over the next five years. There are a variety of companies listed, some of whom may not be able to reach the coveted dividend aristocrat...

Cencora (COR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

November 1, 2024zacks.com

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

October 30, 2024zacks.com

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Cencora (COR) is a Top Growth Stock for the Long-Term

October 28, 2024zacks.com

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Camino Provides Exploration Summary for the Maria Cecilia Copper Porphyry Project in Peru

October 28, 2024accesswire.com

VANCOUVER, BC / ACCESSWIRE / October 28, 2024 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to provide a summary of the summer drilling and exploration campaign at its Maria Cecilia porphyry project ("Maria Cecilia" or...